We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Boehringer Ingelheim has put up $201 million (€173 million) to work with Dicerna Pharmaceuticals on RNAi treatments for NASH and other chronic liver diseases.